PMID- 33275257
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 22
DP  - 2020 Nov
TI  - Protective effect of dexmedetomidine against renal injury in diabetic nephropathy 
      rats through inhibiting NF-kappaB pathway.
PG  - 11865-11870
LID - 23844 [pii]
LID - 10.26355/eurrev_202011_23844 [doi]
AB  - OBJECTIVE: The aim of this study was to investigate the protective effect of 
      dexmedetomidine (Dex) against renal injury in diabetic nephropathy (DN) rats by 
      inhibiting the nuclear factor-kappaB (NF-kappaB) pathway. MATERIALS AND METHODS: A total 
      of 36 Sprague-Dawley rats were randomly divided into three groups, including: 
      normal group (n=12), model group (n=12) and Dex group (n=12). The rats underwent 
      no treatment in normal group. In model group, the diabetes model was successfully 
      established, and normal saline was intraperitoneally injected after operation. In 
      Dex group, the diabetes model was established as well, and Dex was 
      intraperitoneally injected after operation. After intervention for 2 weeks, the 
      samples were taken for use. Blood urea nitrogen (BUN) and serum creatinine (Cr) 
      were detected using a full-automatic biochemical analyzer. The expression of 
      Caspase-3 was detected via immunohistochemistry. Western blotting was conducted 
      to detect the protein expression of NF-kappaB. The apoptosis was detected via 
      terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) 
      assay. In addition, the levels of interleukin-6 (IL-6) and tumor necrosis 
      factor-alpha (TNF-alpha) were determined via enzyme-linked immunosorbent assay (ELISA). 
      RESULTS: The levels of BUN and Cr were significantly higher in model group and 
      Dex group than those in normal group (p<0.05). However, they were significantly 
      lower in Dex group than those in the model group (p<0.05). Immunohistochemistry 
      results showed that the mean optical density of Caspase-3 positive expression 
      increase remarkably in model group and Dex group when compared with normal group 
      (p<0.05). However, it significantly declined in Dex group when compared with the 
      model group (p<0.05). The results of Western blotting revealed that model group 
      and Dex group exhibited evidently higher relative protein expression of NF-kappaB 
      than normal group (p<0.05). However, Dex group displayed notably lower relative 
      protein expression of NF-kappaB than model group (p<0.05). TUNEL assay demonstrated 
      that the apoptosis rate increased significantly in the model group and Dex group 
      when compared with normal group (p<0.05). However, it remarkably declined in Dex 
      group in comparison with the model group (p<0.05). Finally, ELISA assay indicated 
      that model group and Dex group had markedly higher levels of IL-6 and TNF-alpha than 
      normal group (p<0.05). However, the levels of IL-6 and TNF-alpha were significantly 
      lower in Dex group than model group (p<0.05). CONCLUSIONS: Dex inhibits 
      inflammation and apoptosis by suppressing the NF-kappaB signaling pathway, thereby 
      exerting a protective effect against renal injury in DN rats.
FAU - Liu, Y-T
AU  - Liu YT
AD  - Department of Anesthesiology, First Hospital of Lanzhou University, Lanzhou, 
      China. doctorliuyt@163.com.
FAU - Liu, W
AU  - Liu W
FAU - Wan, Z-H
AU  - Wan ZH
FAU - Wang, X-Q
AU  - Wang XQ
FAU - Gu, F-X
AU  - Gu FX
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (NF-kappa B)
RN  - 0 (Protective Agents)
RN  - 5W494URQ81 (Streptozocin)
RN  - 67VB76HONO (Dexmedetomidine)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Dexmedetomidine/administration & dosage/*pharmacology
MH  - Diabetic Nephropathies/chemically induced/*drug therapy/metabolism
MH  - Female
MH  - Injections, Intraperitoneal
MH  - Kidney/*drug effects/metabolism/pathology
MH  - Male
MH  - NF-kappa B/*antagonists & inhibitors/metabolism
MH  - Protective Agents/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin
EDAT- 2020/12/05 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/12/04 12:08
PHST- 2020/12/04 12:08 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
AID - 23844 [pii]
AID - 10.26355/eurrev_202011_23844 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11865-11870. doi: 
      10.26355/eurrev_202011_23844.